Compared with chemotherapy alone, neoadjuvant nivolumab plus chemotherapy extends overall survival in patients with resectable non-small cell lung cancer.
Adding nivolumab to neo adjuvant chemotherapy significantly improved 5-year overall survival among patients with resectable non-small cell lung cancer , according to findings from a phase 3 trial presented at the recent American Society of Clinical Oncology 2025 annual meeting.
The survival benefit was more pronounced in patients who achieved a pathologic complete response or a presurgery clearance of circulating tumor DNA .compared with neoadjuvant chemotherapy alone, nivolumab plus chemotherapy improvespathologic complete response rates and event-free survival in patients with stage IB-IIIA resectable NSCLC. Based on these findings, this regimen was approved for this patient population in the US, EU, and other places. Researchers are now reporting the final, prespecified analysis of overall survival. In the trial, 358 patients with stage IB-IIIA resectable NSCLC were randomly assigned to receive either nivolumab plus platinum-based chemotherapy or platinum-based chemotherapy alone every 3 weeks for three cycles. Surgery was performed within 6 weeks of completing neoadjuvant treatment. Postoperative adjuvant chemotherapy, radiotherapy, or both were permitted. Primary endpoints were event-free survival and pathologic complete response. Overall survival was the key secondary endpoint.The 5-year overall survival rate was 65.4% with nivolumab plus chemotherapy vs 55.0% with chemotherapy alone. Nivolumab plus chemotherapy reduced the risk for death by 28% . The combination therapy was associated with consistent survival benefits across disease stage and PDL-1 expression levels. The 5-year lung cancer-specific survival rate was 74.9% with nivolumab plus chemotherapy vs 65.1% with chemotherapy alone . No new safety concerns emerged, and there were no new deaths related to a trial treatment.“In this trial, we found that the use of neoadjuvant nivolumab plus chemotherapy resulted in significantly longer overall survival than chemotherapy alone, along with long-term benefit regarding event-free survival,” the authors wrote. “These findings support the hypothesis that neoadjuvant chemoimmunotherapy can have a profound impact on the course of a patient’s life when paired with the curative potential of surgical resection.”This study, led by Patrick M. Forde, MB, BCh, PhD, Trinity St. James’s Cancer Institute, Trinity College Dublin, Dublin, Ireland, wasAlthough the overall survival with nivolumab plus chemotherapy achieved statistical significance, the margin was narrow. Additionally, several subgroups in the exploratory analyses were too small for adequate statistical comparison, requiring cautious interpretation of these results. Black patients were underrepresented, which may have affected the generalizability of the findings.This study was funded by Bristol Myers Squibb. Five authors declared being employees of Bristol Myers Squibb, with some holding stock or stock options with the company. Several authors declared working as consultants or having other ties with various sources including Bristol Myers Squibb. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties.
Lung Carcinoma Cancer Of The Lung Chemotherapy Adjuvant Chemotherapy Non-Small Cell Lung Cancer NSCLC Non-Small Cell Lung Cancer (NSCLC) Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Lung Neoadjuvant Surgery Platinum
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Plutus Launches PLUS More on Base: A New Era of Tokenised Loyalty RewardsCrypto Blog
Read more »
Hannah Gosselin Reflects on Jon and Kate Plus 8, Trick to Avoid FilmingHannah Gosselin reflected on growing up in the public eye after being featured in TLC's series 'John and Kate Plus 8'
Read more »
Can Nivolumab Maintain AML Remission?For acute myeloid leukemia remission, nivolumab maintenance therapy shows no benefit.
Read more »
Adjuvant Nivolumab + CRT Improves Disease-Free Survival in Head and Neck CancerPostoperative nivolumab added to standard-of-care adjuvant cisplatin radiotherapy “represents a potential new standard.”
Read more »
Targeted Therapy Wins Big for BRAF-Mutated Metastatic CRCEncorafenib plus cetuximab with chemotherapy is being called the new first-line standard for BRAF V600E-mutant metastatic colorectal cancer following new trial results.
Read more »
5 Proud Boys sue US government over Jan. 6 prosecutionsIt seeks unspecified compensatory damages plus 6% interest and $100 million plus interest in punitive damages.
Read more »